Valuation models
price $106.20 · as of Nov 2, 2026
DCF · Perpetuity growth · 5yused87.52 – 137.10106.921% undervaluedDCF · Perpetuity growth · 10y97.93 – 152.86119.4211% undervaluedDCF · EBITDA exit · 5y147.46 – 161.00154.0431% undervaluedDCF · EBITDA exit · 10y148.89 – 175.16161.3934% undervaluedP/E · peers82.81 – 159.91110.184% undervaluedP/E · own history113.08 – 146.12127.4117% undervaluedPEG—102.733% overvaluedEV/EBITDA · peers97.89 – 177.14114.277% undervaluedEV/Revenue · peers89.75 – 187.39142.3825% undervaluedEarnings power value29.19 – 45.2435.63198% overvaluedDividend discount47.09 – 121.7970.8050% overvaluedWall St. consensus target—121.5013% belowCost of capital (WACC)—7.61%—
DCF · Perpetuity growth · 5y leads for a mature, steady company — positive operating income and three years of positive free cash flow. How the headline model is chosen.
Model value · DCF · Perpetuity growth · 5y
106.92
Abbott Laboratories closed at $106.20 — undervalued by 1% vs model.
87.52the model's range137.10
DCF · Perpetuity growth · 5y leads for a mature, steady company — positive operating income and three years of positive free cash flow. From a five-year discounted cash flow.
Other models
35.63 – 161.39
Wall St. target
121.50 13% below
Below model, 1y
17 of 31 days
How it is valued
Valued asMature & stable
Low/slowing growth (~5% recent)Moderate margins (15% net margin)Pays dividendsHighly cyclical earnings
Model estimates for research reference only, not investment advice. Every model rests on assumptions that may not match what happens; how each model works is in the manual.